Improving decay-accelerating factor (DAF, CD55) by substituting a GPI-anchor with a membrane-targeting address

被引：0
|
作者：
White, J
Giddings, N
Esser, D
Thurston, K
Steward, M
Bright, JR
Morgan, BP
Smith, GP
Smith, RAG
机构：
[1] AdProTech, Saffron Walden CB10 1XL, Essex, England
[2] Univ Wales Coll Med, Dept Med Biochem, Cardiff CF4 4XN, S Glam, Wales
来源：
MOLECULAR IMMUNOLOGY | 2001年 / 38卷 / 2-3期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
131
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [31] Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF,CD55) and membrane cofactor protein (MCP,CD46) on a human colonic adenocarcinoma cell line
    Bjorge, L
    Jensen, TS
    Matre, R
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (03) : 185 - 192
  • [32] Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/Ipr mice
    Miwa, T
    Maldonado, MA
    Zhou, L
    Sun, XJ
    Luo, HY
    Cai, DW
    Werth, VP
    Madaio, MP
    Eisenberg, RA
    Song, WC
    AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (03): : 1077 - 1086
  • [33] Effect of immunosuppressive drugs on the decay-accelerating factor (CD55); implications for a subset of myasthenia gravis patients
    Abrahams, A.
    Auret, J.
    Prince, S.
    Heckmann, J. M.
    FEBS JOURNAL, 2011, 278 : 322 - 322
  • [34] Discovery, linkage disequilibrium and association analyses of polymorphisms of the immune complement inhibitor, decay-accelerating factor gene (DAF/CD55) in type 1 diabetes
    Hidenori Taniguchi
    Christopher E Lowe
    Jason D Cooper
    Deborah J Smyth
    Rebecca Bailey
    Sarah Nutland
    Barry C Healy
    Alex C Lam
    Oliver Burren
    Neil M Walker
    Luc J Smink
    Linda S Wicker
    John A Todd
    BMC Genetics, 7
  • [35] Discovery, linkage disequilibrium and association analyses of polymorphisms of the immune complement inhibitor, decay-accelerating factor gene (DAF/CD55) in type 1 diabetes
    Taniguchi, Hidenori
    Lowe, Christopher E.
    Cooper, Jason D.
    Smyth, Deborah J.
    Bailey, Rebecca
    Nutland, Sarah
    Healy, Barry C.
    Lam, Alex C.
    Burren, Oliver
    Walker, Neil M.
    Smink, Luc J.
    Wicker, Linda S.
    Todd, John A.
    BMC GENETICS, 2006, 7 (1)
  • [36] Decay accelerating factor (CD55): A target for cancer vaccines?
    Spendlove, I
    Li, L
    Carmichael, J
    Durrant, LG
    CANCER RESEARCH, 1999, 59 (10) : 2282 - 2286
  • [37] COXSACKIEVIRUS B3 ADAPTED TO GROWTH IN RD CELLS BINDS TO DECAY-ACCELERATING FACTOR (CD55)
    BERGELSON, JM
    MOHANTY, JG
    CROWELL, RL
    JOHN, NFS
    LUBLIN, DM
    FINBERG, RW
    JOURNAL OF VIROLOGY, 1995, 69 (03) : 1903 - 1906
  • [38] FLOW CYTOMETRIC ANALYSIS OF DECAY-ACCELERATING FACTOR (CD55) ON NEUTROPHILS FROM APLASTIC-ANEMIA PATIENTS
    FORES, R
    ALCOCER, M
    DIEZMARTIN, JL
    FERNANDEZ, MN
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (03) : 728 - 730
  • [39] Antiadhesive role of apical decay-accelerating factor (CD55) in human neutrophil transmigration across mucosal epithelia
    Lawrence, DW
    Bruyninckx, WJ
    Louis, NA
    Lublin, DM
    Stahl, GL
    Parkos, CA
    Colgan, SP
    JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (07): : 999 - 1010
  • [40] Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer
    Holla, VR
    Wang, DZ
    Brown, JR
    Mann, JR
    Katkuri, S
    Dubois, RN
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (01) : 476 - 483
12345